Study of enzyme therapy for children with infant-onset Pompe disease
Part of Genetic & congenital, Hormones & metabolism clinical trials.
This trial tests how well a new enzyme treatment (cipaglucosidase alfa with miglustat) works and how safe it is in children and babies with infant-onset Pompe disease. It may help by improving muscle function after earlier treatment or, for some babies, starting treatment when no prior enzyme therapy has been given.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your child) are between 6 months and under 18 years, or between 0 and under 6 months for the baby group
- The Pompe disease genetic test (genotype) is documented
- You were diagnosed with hypertrophic cardiomyopathy (an enlarged heart muscle) at the time of diagnosis
- Group 1 must have taken enzyme replacement therapy (ERT) for at least 6 months before enrollment (or at least 3 months on any changed dose plan); Group 2 must not have had ERT before
- Your child has shown clinical decline despite the current rhGAA treatment dose (Group 1)
- No need for invasive ventilation (for example, a tracheostomy) and no history of severe allergy reactions to these medicines
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests the safety and effects of the enzyme replacement therapy avalglucosidase alfa (Nexviazyme) in children with infantile-onset Pompe disease. It is for children who have had Pompe symptoms since infancy and heart problems at diagnosis.
This trial tests if getting enzyme replacement therapy every 4 weeks instead of every 2 weeks is safe and effective for stable adults with late-onset Pompe disease. It may reduce the burden of frequent infusions.
This early-stage trial tests a new gene therapy for adults with late-onset Pompe disease who have already tried enzyme replacement therapy (ERT). The goal is to see if the gene therapy is safe and can help improve muscle strength and breathing.
This trial tests a new gene therapy for late-onset Pompe disease. The therapy aims to help your body produce the enzyme needed to break down glycogen, which may improve muscle and breathing function.
This study tests a one-time gene therapy (AB-1009) for adults with late-onset Pompe disease. It aims to see if the treatment is safe and improves muscle and breathing function.
This is a registry study that collects information over time from people with Pompe disease. It helps doctors and researchers better understand the condition and how it affects daily life, without testing any new treatments.
Hear when a new Glycogen Storage Disease Type II Infantile Onset trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.